Business Wire

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Share

Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium (GTC, consisting of researchers from Imperial College London and the Universities of Oxford and Edinburgh) and Oxford Biomedica (OXB), announced today that Boehringer Ingelheim has exercised its options on intellectual property and know-how from the partners to progress and further accelerate the development of a potential, new treatment option for patients with CF. In the partnership, IP Group, acting on behalf of the three GTC host Universities, is granting exclusive global rights to develop, manufacture, register, and commercialize this lentiviral vector-based gene therapy for the treatment of cystic fibrosis. The GTC is additionally contributing its knowledge in pre-clinical research and clinical gene therapy development. OXB is adding its leading competence in manufacturing lentiviral vector-based therapies to Boehringer Ingelheim’s expertise in the development of novel breakthrough therapies for respiratory diseases.

CF is a rare, progressive, life-threatening disease that results in severe dysfunction and persistent infections of the lung affecting 70,000 people worldwide. It is caused by a defective or absent protein that results from mutations in the CFTR gene. This innovative development partnership among academia, life science investors, pharma, and biotech focusses on the advancement of BI 3720931, a novel, replication deficient lentiviral vector, in an inhaled formulation, which selectively introduces a healthy CFTR gene into the relevant target cells.

Professor Eric Alton, Coordinator of the GTC, said: “The novel lung-targeting technology we have developed has demonstrated high gene transfer efficiency in pre-clinical models and offers the possibility of repeated administration to maintain a therapeutic effect, a benefit that other viral-based gene therapies may not be able to provide. Our novel therapy has the potential to improve CFTR function and modify disease in all CF patients, independent of the more than 2,000 different known gene mutations. The immediate target is those patients who are not eligible for CFTR modulators. The GTC is very excited to have reached this milestone after 21 years of focused effort. We are very grateful to our wonderful team and those with CF who have supported us in many ways including taking part in the multiple trials. We would like to thank our funders, both past and present, including the Health Innovation Challenge Fund (a partnership between Wellcome and the Department of Health and Social Care) and Just Gene Therapy, as well as the CF Trust, National Institute for Health Research and the Medical Research Council.”

“Since 2018, Boehringer Ingelheim has sponsored research and development activities with the GTC and OXB. The shared success achieved with our partners in this potentially revolutionary project makes us confident that we can now further accelerate this highly innovative therapeutic approach,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “With our leadership in the discovery and development of therapies in respiratory diseases combined with the gene therapy and manufacturing knowledge of our partners, we aim to bring the next breakthrough to patients suffering from CF, who are desperately waiting for better options.”

John Dawson, Chief Executive Officer of Oxford Biomedica, said: “We have enjoyed working with Boehringer Ingelheim, IP Group, and the GTC since 2018. Building on the great progress made to date, we are delighted that Boehringer Ingelheim, one of the world’s leading respiratory medicine organizations, has chosen to exercise the option to license OXB lentiviral vector manufacturing technology for this highly innovative inhaled cystic fibrosis gene therapy formulation developed by the GTC. This partnership is central to our company’s mission of delivering life changing gene therapies to patients and has the potential to provide a new therapeutic option for many cystic fibrosis patients globally.”

Under the terms of the option and license agreement with Boehringer Ingelheim, originally announced in August 2018, Boehringer Ingelheim will pay IP Group, on behalf of the GTC, an option exercise fee, near term, success based development, regulatory and sales milestone payments as well as royalties on net sales. OXB will receive an option exercise fee of £3.5 million and will be entitled to payments in an aggregate amount of up to £27.5 million upon achievement of various development, regulatory and sales milestones, in addition to a tiered low single digit royalty on net sales of a cystic fibrosis gene therapy product.

David Ramsden, Chief Executive of the Cystic Fibrosis Trust said: “It is great news that Boehringer Ingelheim have committed to the next stage of the development of a gene therapy treatment for people with cystic fibrosis. This is an important step as it brings hope to the whole cystic fibrosis community and in particular to those who don’t benefit from the currently available medicines. All of those who have helped us to invest long term in the work of the UK CF Gene Therapy Consortium should be proud of what they have made possible.”

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/cystic-fibrosis-genetherapy-development-option-excercise

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:

Boehringer Ingelheim
Dr Reinhard Malin

Head of Innovation Unit Communications
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
press@boehringer-ingelheim.com

UK Cystic Fibrosis Gene Therapy Consortium

Imperial College London

Professor Eric Alton
P: +44-207-594-7937
e.alton@ic.ac.uk

Professor Uta Griesenbach
P: +44-207-594-7927
u.griesenbach@ic.ac.uk

Professor Jane Davies
P: +44-207-594-7973
j.c.davies@ic.ac.uk

University of Oxford

Professor Deborah Gill
P: +44-1865 750300
deborah.gill@ndcls.ox.ac.uk

Professor Stephen Hyde
P: +44-1865 750300
steve.hyde@ndcls.ox.ac.uk

University of Edinburgh

Dr Christopher Boyd
P: +44-131-651-8733
chris.boyd@ed.ac.uk

Dr Gerry McLachlan
P: +44-131-651-9162
gerry.mclachlan@roslin.ed.ac.uk

Oxford Biomedica

Mary-Jane Elliott / Matthew Neal
Consilium Strategic Communications: T: +44 (0)20 3709 5700

University of Edinburgh | Oilthigh Dhùn Èideann

Shane Canning
Press Office | Oifis nam Meadhanan
PR & Media Manager (Medicine & Vet Medicine) | Manaidsear PR & na Meadhanan
M 0755 782 0266 | E shane.canning@ed.ac.uk | @EdinUniMedia

University of Oxford News Office

P: + 44 (0)1865 280528
news.office@admin.ox.ac.uk

Imperial College

Ryan O’Hare
Senior Media Officer
Phone: +44 (0)20 7594 2410
Email: r.ohare@imperial.ac.uk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wordley Partnership: New Partner Appointments Bolster Insurance, Commercial Litigation, International Arbitration and Corporate Practice7.12.2021 22:49:00 EET | Press release

International law firm Wordley Partnership has appointed two new partners, Costas Frangeskides and Simon Schindler. The appointments boost Wordley Partnership’s Insurance sector and Commercial groups. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207006028/en/ Costas Frangeskides (Photo: Business Wire) Brief biographies are enclosed below: Costas is based in London and joins from leading international practice Holman Fenwick Willan (HFW) where he had been a partner since 2002 and is highly experienced in insurance and reinsurance disputes, commercial law, and international arbitration. He has a proven track record and has handled many high-profile commercial and insurance disputes. Commenting on the appointments, managing partner Paul Wordley of Wordley Partnership said: "We are delighted to announce Costas and Simon joining our team. This demonstrates our continuing commitment and expertise in the insurance markets, and

New Data Reveals Social Presence and Engagement Key to Streaming Growth7.12.2021 21:42:00 EET | Press release

Roughly 80% of social engagement for streaming platforms comes from Instagram, with TikTok close behind thanks to accounts like Netflix growing by more than a million followers each month in 2021. This is according to the Social Guide for Streaming report from Conviva, the continuous measurement platform for streaming media, which examined social engagement for more than 87 global streaming platforms and 695 streaming TV shows from January 1, 2021 to October 21, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005982/en/ Conviva’s State of Streaming: Social Guide for Streaming 2021 Publishers Report (Graphic: Business Wire) “A strong presence on social platforms like Facebook, Twitter and Instagram is critical for streaming publishers as it has been proven social is a key to content discovery,” said Keith Zubchevich, CEO, Conviva. “And, it’s not just about posting volume. The publishers that creatively and regularl

Andersen Global Strengthens European Platform with Addition of Collaborating Firm in Czech Republic7.12.2021 20:15:00 EET | Press release

Andersen Global enters into a Collaboration Agreement with Prague-based law firm rutland & partners, adding breadth to its platform in Europe. Rutland & partners, established in 2010 by Founding Partner Monika Rutland, focuses on corporate, real estate and M&A, providing legal services to businesses, foreign entities and private clients. Recognized by Chambers & Partners and The Legal 500, the firm offers full-service capabilities in litigation, employment, immigration, construction, pharmaceuticals and health care, banking, trust, and IT law. “Establishing long-lasting relationships and providing clients with quality, comprehensive solutions are integral aspects of our value-added service,” said Monika. “Our collaboration with Andersen Global further equips us to provide a seamless, integrated suite of services so clients can achieve their business objectives at the local and international levels.” Andersen Global Chairman and Andersen CEO Mark Vorsatz added, “rutland & partners compe

i2c Sets Industry Record with More Than 20 New Implementations Across 10 Markets in November7.12.2021 18:21:00 EET | Press release

i2c Inc., a leading provider of digital payment and banking technology, today announced it had deployed more than 20 new payment and digital banking programs for clients across 10 markets and four continents during the month of November alone. “The growth levels combined with the diversity of customers and programs we’re witnessing in our business today is a testament to our growth strategy and global team,” said Amir Wain, founder and CEO of i2c Inc. “We are thrilled to be the enabler of choice for visionaries in the payments and digital banking space as they work to accelerate financial innovation and expand access to millions of end users worldwide,” he said. i2c powers industry leaders in fintech, digital banking, cryptocurrency, as well as traditional financial institutions on a single, agile global platform. This fiscal half’s success includes new enterprise partners, as well as product and global program expansions for several U.S. and international programs, including: 1derful

Sunny Varkey Launches Tmrw, a New Learning Operating System (LearnOS) for Global Education to Bring a Quality Education Within Reach of Every Child7.12.2021 17:48:00 EET | Press release

Tmrw, a new and scalable Learning Operating System (LearnOS) for global education with a mission to help bring a quality education to every child, was launched this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005768/en/ Sunny Varkey, Chairman and Founder of Tmrw (Photo: Business Wire) Its interoperable All-In-One Integrated Platform is built to be accessible and affordable for Government funded schools operating in both the developed and developing world settings. In particular, it seeks to reach all students irrespective of their background or their ability to pay. It is designed to cater to the needs of every curriculum, context and mode of learning, whether brick and mortar, virtual or blended. Tmrw’s vision over time is to underpin learning, teaching, and the operational needs of K12 education, higher education and life-long learning. Sunny Varkey, who also founded the Global Teacher Prize, has ensured th

Nexo Expands Institutional Access to Crypto in Collaboration with Fidelity Digital Assets7.12.2021 17:30:00 EET | Press release

Nexo , the leading regulated institution for digital assets, today announced its collaboration with Fidelity Digital AssetsSM, a leading institutional focused execution and custody services platform provider, to revolutionize institutional access to digital assets by together offering best-in-class custodial and lending services, including the launch of innovative institutional-focused products. Nexo, a pioneer of cryptocurrency-collateralized credit, and Fidelity Digital Assets as custodian and collateral agent, will develop a comprehensive product suite and compliant infrastructure for institutional investors seeking exposure to digital assets. As a first step, the collaboration with Fidelity Digital Assets will expand Nexo’s ability to service and enhance its growing portfolio of assets under management and will provide an additional custody layer to Nexo’s military-grade security infrastructure. This latest development gives institutional investors who currently custody their digit

Percona Platform Unifies Open Source Databases, Supports Private Database-as-a-Service Deployments7.12.2021 17:20:00 EET | Press release

Percona, a leader in open source database software and services, today announced Percona Platform to bring together database distributions, support expertise, services, management and automated insights into a single product. Building on the company’s expertise with databases including MySQL, PostgreSQL and MongoDB, the new Percona Platform will simplify how users monitor, manage and optimize their database instances across any infrastructure. In addition, Percona Platform will enable developers and database administrators to run their own private Database-as-a-Service (DBaaS) instances. This launch will preview the Percona Platform, allowing users to unify the entire database experience from packages and backup to monitoring and management, with general availability in early 2022. Percona brings together distributions of MySQL, PostgreSQL and MongoDB including a range of open source tools for data backup, availability and management. It also includes Percona Monitoring and Management

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom